Galliprant for dogs: evidence, safety, and FDA status

Bottom line: Galliprant (grapiprant tablets) is FDA approved for control of pain and inflammation associated with osteoarthritis in dogs. It is a prescription NSAID with important patient-screening, monitoring, medicine-combination, and adverse-reaction considerations. The approval does not establish that it is appropriate for every dog or superior to every alternative.

Educational information only. This record does not diagnose osteoarthritis, choose a treatment, reproduce a dose, or replace a veterinarian’s assessment of a dog’s history, examination, other medicines, and monitoring needs.

1. Treatment and scope

This record covers Galliprant, the brand name for grapiprant tablets, for the FDA-defined use of controlling pain and inflammation associated with osteoarthritis in dogs. The client information sheet describes oral use in dogs only and states that federal law restricts the product to use by or on the order of a licensed veterinarian.

The scope does not silently extend to cats, another species, an undiagnosed cause of pain, a compounded preparation, or an extra-label decision. The relevant treatment question begins with a veterinary diagnosis and an agreed treatment goal.

2. Regulatory status

FDA approved — defined scope: The FDA approval record is NADA 141-455, with an original approval date of March 20, 2016. The approved indication is control of pain and inflammation associated with osteoarthritis in dogs. The status and current package insert were checked August 18, 2026.

FDA approval does not mean that the product is suitable for every patient, free of adverse effects, superior to every alternative, or approved for a different use involving the same ingredient.

3. Evidence stage

FDA-reviewed target-species evidence: The pivotal placebo-controlled, masked field study enrolled 285 client-owned dogs, and 262 were included in the effectiveness analysis.

After 28 days, 48.1% of Galliprant-treated dogs met the owner-assessed treatment-success definition, compared with 31.3% of control dogs. The outcome was based on the Canine Brief Pain Inventory, an owner assessment of pain and function.

The study lasted 28 days, used an owner-assessed outcome, and applied defined enrollment and exclusion criteria. It therefore does not establish a universal response, lifetime effectiveness, or long-term comparative superiority over other treatments.

4. Benefits, limits, and safety

The supported clinical question is control of pain and inflammation associated with osteoarthritis. The record does not claim joint repair, a cure, or a guaranteed functional improvement.

Galliprant is a non-steroidal anti-inflammatory drug. The label says not to use it in dogs with hypersensitivity to grapiprant and recommends using the lowest effective dose for the shortest duration consistent with the individual dog’s response.

Before NSAID therapy, the label recommends a thorough history and physical examination and appropriate laboratory testing to establish hematologic and serum biochemical baseline data. Periodic laboratory testing and follow-up should be considered during use, particularly during long-term treatment.

Galliprant should not be administered with another oral or injectable NSAID or a corticosteroid. Safe use has not been evaluated in dogs younger than nine months and weighing less than eight pounds, dogs used for breeding, or pregnant or lactating dogs. Dogs described by the label as being at greatest risk for NSAID-associated adverse events include those that are dehydrated, receiving diuretic therapy, or have existing renal, cardiovascular, or hepatic dysfunction.

Reactions reported in the controlled field study included vomiting, diarrhea or soft stool, decreased appetite, lethargy, and changes in albumin or total protein. The post-approval section also lists gastrointestinal ulceration or bleeding, elevated pancreatic or liver enzymes, kidney and urinary problems, ataxia, seizures, anemia, thrombocytopenia, and allergic reactions. In some reports, death or euthanasia was an outcome. Because post-approval reports are voluntary, they cannot reliably establish event frequency or causation. Do not start, stop, combine, or substitute medicines based on this record.

5. Cost data status

No treatment-price range is published yet. This page currently explains cost components only.

It will be updated when the Index has enough source-dated, location-labeled observations to show a clearly limited sample without implying a national or typical price.

Until then, request an itemized estimate that separates the examination, diagnostics, drug or administration, monitoring, repeat purchases, and other care. A single product, dose, or visit price is not necessarily the complete cost of treatment.

6. Insurance status and variables

This page does not determine whether a claim is covered, and no treatment-specific policy comparison has been completed.

Coverage depends on the policy form, state, version or effective date, waiting period, pre-existing-condition terms, applicable treatment category, deductible, reimbursement percentage, limits, exclusions, and claim facts. Use the actual policy and a written insurer response for a specific claim.

7. Legitimate access

The official client information states that federal law restricts Galliprant to use by or on the order of a licensed veterinarian. Legitimate access begins with a veterinary evaluation and a prescription decision. This page is not a pharmacy, does not sell the product, and does not provide dosing instructions.

8. Established alternatives

Depending on diagnosis and patient factors, a veterinarian may discuss other pain-management medicines, rehabilitation, activity or home-environment changes, weight management, supportive care, referral, or a different plan. The relevant comparison includes indication, expected outcome, safety, monitoring, cost, coverage, and access. This record does not declare a universal winner.

9. Appropriate next step

If a veterinarian has raised Galliprant, ask:

• What diagnosis and treatment goal are we addressing?
• What current medicines, supplements, or health conditions affect the safety discussion?
• What benefit will we measure, and when will we reassess?
• What are the complete expected costs and repeat-purchase requirements?
• Which policy provisions and pre-existing-condition rules may matter?
• Which established alternatives belong in the same comparison?

Sources and claim verification

1. FDA FOI Summary, NADA 141-455 — supports the March 20, 2016 approval date, dog indication, effectiveness review, and target-animal-safety review; checked August 18, 2026.
2. Galliprant package insert — supports the labeled indication, dog-only use, prescription restriction, warnings, precautions, and administration context; label checked August 18, 2026.
3. Galliprant client information sheet — supports the dog-only oral-use and prescription-access statements; checked August 18, 2026.

Change log

• August 19, 2026: Added the pivotal field-study size and treatment-success result; added current warnings, monitoring recommendations, medicine-combination restrictions, higher-risk patient factors, and post-approval adverse-event categories.